Artificial Corneal Implants Market (2023 - 2030) Size, Share & Trends Analysis Report By Transplant Type (Hard Keratoprosthesis, Soft Keratoprosthesis), By Indication (Ocular Burns, Keratoconus), By Implant Type, By Region, And Segment Forecasts

Artificial Corneal Implants Market Summary

The COVID-19 pandemic had a significant negative impact on the artificial corneal implants market. The lockdowns and restrictions implemented by governments had a major impact on the market. With changes in healthcare priorities and the healthcare professionals dedicatedly working to treat and control the spread of the virus, elective surgeries were either canceled or postponed.

Moreover, in order to control the spread of the virus and as a preventive measure, many people avoided visits to hospitals or any other healthcare setting. This resulted in an overall drop in the number of corneal transplants that were carried out during the pandemic, which led to a negative impact on the market. However, due to the presence of a huge patient pool and a rising number of product launches, the artificial corneal implants market recovered at a great pace. In addition, with an increased focus on R&D in the healthcare sector by governments, the market is further expected to flourish over the forecast period. 

The market is predominantly driven by a rise in the prevalence of eye disorders. An increase in the occurrence of eye-related disorders, such as keratoconus, ocular cicatricial pemphigoid, corneal stromal dystrophies, and infectious keratitis, is a major market driver. Studies suggest that Keratoconus affects approximately 50 to 200 per 100,000 individuals. In the U.S., the prevalence is about 54.5 per 100,000 individuals.

Corneal blindness is the third leading cause of blindness after glaucoma and cataract, affecting 10 million people globally. According to a research article published by the Eye Bank Association of America in 2021, an estimated 200,000 corneal implant procedures are performed annually. Artificial corneal implantation typically applies to patients who are not suited for a living corneal transplant from a human donor to regain their vision.

According to an article from Harvard Medical School, about 12.7 million individuals worldwide are waiting for corneal transplants, implying that only 1 in every 70 persons in need of a transplant is treated. Significant attempts have been made to create alternatives to human donor corneas to address the scarcity of donor tissue and the problems associated with corneal donor transplantation, thus augmenting the adoption of artificial corneal implants.

Furthermore, in low-risk patients with corneal blindness, corneal transplantation is successful, but it frequently fails in high-risk patients with recurring or chronic inflammatory disorders, as well as glaucoma. Another major factor driving the market growth is the large patient pool and limited supply of donors.

Transplant Type Insights

The hard keratoprosthesis segment dominated the market and accounted for a revenue share of 87.47% in 2022. This is due to the higher adoption of these products, especially Boston Kpro. It is the most widely used artificial cornea and continued advances in design and superior postoperative care have resulted in improved outcomes and an exponential increase in the use of the device in recent years. According to a research paper published in 2022 by the department of ophthalmology of Harvard Medical School, there have been more than 11,000 implantations to date in 66 countries by 598 surgeons using Boston Kpro.

However, the soft keratoprosthesis segment is expected to experience maximum growth over the forecast period owing to new product launches. For instance, in February 2020, EyeYon Medical Ltd. announced Breakthrough Status Designation from the U.S. Food and Drug Administration (FDA) for its EndoArt, Artificial Endothelial Layer Implant. The company received CE Mark as well for its EndoArt Implant to treat chronic corneal edema in June 2021.

Indication Insights

In 2022, the keratoconus segment held the highest market share of 33.93% owing to the increasing prevalence of keratoconus worldwide. According to the Cancer Research Foundation of America, 1 in 5 keratoconus patients progresses to a stage where a corneal implant is needed to restore normal vision. The rising usage of artificial corneal implants in patients with keratoconus is further expected to drive segment growth over the forecast period.

The Ocular Cicatricial Pemphigoid (OCP) segment is projected to undergo maximum growth over the forecast period. Growing awareness regarding eye disorders is the major factor driving the growth of the segment. The ocular burns segment is also expected to undergo significant growth over the forecast period due to the growing number of burn cases across different settings.

Implant Type Insights

The synthetic segment dominated the market and accounted for a revenue share of 93.7% in 2022. This is due to the higher presence of synthetic artificial corneal implants in the market as compared to biosynthetic products, thus leading to a higher adoption rate. Moreover, companies are focusing on developing artificial corneal implants that are synthetic. For instance, CorNeat Kpro, which is under clinical trials and is expected to launch in 2023, is a synthetic cornea, which provides a long-lasting medical solution for corneal blindness, pathology, and injury.

With an increasing number of manufacturers focusing on developing synthetic corneal implants and a strong product pipeline, the segment is expected to experience exponential growth as well. Moreover, due to this shift towards synthetic corneal implants, the biosynthetic segment is projected to experience limited growth over the forecast period.    

End-use Insights

The hospital segment accounted for the highest revenue share of 57.5% in 2022 and is expected to register a lucrative CAGR over the forecast period. The presence of highly skilled surgeons and the rising number of patients are the factors expected to drive segment growth.

On the other hand, the ambulatory surgical center (ASC) segment is anticipated to register maximum growth over the forecast period. The growing popularity of Ambulatory Surgical Centers (ASCs) is expected to help the segment gain a significant share over the forecast period. Corneal implant procedures are performed on an outpatient basis in most care settings.

Regional Insights

North America dominated the artificial corneal implants market with the largest revenue share of 50.9% in 2022. The presence of a large patient pool, the availability of technologically advanced products that make the procedures simple, and a favorable reimbursement scenario are factors responsible for the dominance of the region in the global artificial corneal implants market. Moreover, the increasing focus of the regional governments on R&D activities is also significantly driving the growth of the market in this region. In addition, the shortage of human cornea despite having the highest number of donors in the U.S. is also expected to drive the artificial corneal implants market in this region.

In Asia Pacific, the market is expected to experience maximum CAGR over the forecast period. A large patient pool in countries like India and China, the presence of manufacturers, and the regional launch of products are factors driving the growth of the market in this region. Moreover, growing awareness regarding ocular disorders and increasing disposable income are also contributing to significant growth of the market.

Key Companies & Market Share Insights

In order to establish a strong position and strengthen their overall presence, manufacturers in the market are concentrating on carrying out various strategic initiatives. This includes partnerships & collaborations, acquisitions & mergers, expansions, and increasing investment in R&D.

Key players in the market are focusing on launching new products in the market and receiving regulatory approvals in different countries in order to expand the reach of their products and generate higher revenue. For instance, in June 2021, after clinical trials established the safety and efficacy for treating chronic corneal edema, EyeYon received CE Mark for its EndoArt, the world's first and only synthetic implant that replaces the human endothelium, which cannot be regenerated by the human body. Some of the prominent players in the global artificial corneal implants market include:

• FCI Ophthalmics, Inc.

• Beijing Microkpro Medical Instrument Co. Ltd.

• DIOPTEX Medizinprodukte Forschungs

• KeraMed, Inc.

• EyeYon

Artificial Corneal Implants Market Report Scope

Global Artificial Corneal Implants Market Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For the purpose of this study, Grand View Research has segmented the global artificial corneal implant market report on the basis of transplant type, indication, implant type, end-use, and region:

• Transplant Type Outlook (Revenue, USD Million, 2018 - 2030)

  • Hard Keratoprosthesis

    • Boston Kpro

    • Osteo-Odonto-Keratoprosthesis

  • Soft Keratoprosthesis

• Indication Outlook (Revenue, USD Million, 2018 - 2030)

  • Stevens-Johnson syndrome (SJS)

  • Ocular Cicatricial Pemphigoid (OCP)

  • Ocular burns

  • Keratoconus

  • Corneal stromal dystrophies

  • Others

• Implant Type Outlook (Revenue, USD Million, 2018 - 2030)

  • Synthetic

  • Biosynthetic

• Implant End-use Outlook (Revenue, USD Million, 2018 - 2030)

  • Hospitals

  • Ophthalmic Centers

  • Ambulatory Surgical Centers

• Regional Outlook (Revenue, USD Million, 2018 - 2030)

  • North America

  • U.S.

  • Canada

  • Europe

  • Germany

  • U.K.

  • France

  • Italy

  • Spain

  • Denmark

  • Sweden

  • Norway

  • Asia Pacific

  • Japan

  • India

  • China

  • South Korea

  • Thailand

  • Australia

  • Latin America

  • Brazil

  • Mexico

  • Argentina

  • Middle East & Africa

  • South Africa

  • Saudi Arabia

  • UAE

  • Kuwait